Por Renan Filho · 2026-11-06**Lead**
A major new study has found that even occasional marijuana use is associated with a significantly higher risk of stroke, a finding that is already reshaping the political landscape around cannabis legalization in the United States. The research, conducted by a team of epidemiologists and published in a peer-reviewed journal, analyzed health data from tens of thousands of adults over a multiyear period. While the study does not prove causation, the strength of the association has prompted urgent calls from public health officials for a reassessment of current drug policies, particularly as more states move toward legalization for recreational use.
**Context**
Marijuana is now legal for recreational use in 24 states and the District of Columbia, and medical use is permitted in 38 states. The federal government, however, still classifies cannabis as a Schedule I controlled substance under the Controlled Substances Act, alongside heroin and LSD. This legal contradiction has created a patchwork of regulations and a booming industry worth tens of billions of dollars. The Biden administration has taken steps to reschedule marijuana to Schedule III, a move that would acknowledge its medical value but still impose federal restrictions. The new stroke study injects a fresh dose of caution into that process.
The study, which drew on data from the National Health and Nutrition Examination Survey and hospital records, focused on adults aged 18 to 65 who reported using marijuana at least once in the past year. Even after controlling for known risk factors such as smoking tobacco, alcohol use, and preexisting cardiovascular conditions, researchers found a clear statistical link between marijuana use and stroke. The risk was elevated not only for heavy users but also for those who used marijuana as infrequently as once a month. The findings align with earlier, smaller studies that suggested cannabis can cause temporary spikes in blood pressure and heart rate, and may promote arterial inflammation.
Public health experts have long warned that the narrative around marijuana as a harmless substance is misleading. Dr. Nora Volkow, director of the National Institute on Drug Abuse, has previously testified before Congress about the need for more research on cannabis-related health risks. The new study provides the kind of large-scale evidence that lawmakers have been demanding. Several members of Congress, including Senator Joe Manchin of West Virginia and Representative Debbie Dingell of Michigan, have already cited the research in statements calling for a slower, more deliberate approach to federal legalization.
**Analise**
The political implications of this study are profound. For years, the push for legalization has been driven by arguments about personal freedom, criminal justice reform, and economic opportunity. The marijuana industry has spent heavily on lobbying and campaign contributions, and many Democratic and some Republican lawmakers have embraced legalization as a popular stance. But the stroke risk finding threatens to shift the debate toward public health and safety. If even occasional use can cause irreversible damage, the argument that marijuana is no more dangerous than alcohol – a common refrain – becomes harder to sustain.
At the state level, governors and legislators are now facing a dilemma. States like New York, California, and Colorado have built significant tax revenue streams around legal cannabis. Any move to roll back legalization would be politically and economically costly. However, the study gives ammunition to opponents, including conservative groups and some medical associations, who have long warned that legalization would lead to increased health care costs and emergency room visits. In states where legalization is on the ballot in upcoming elections, the study could tip the balance. For example, in Florida, where a constitutional amendment to legalize recreational marijuana is being considered, opponents are already using the stroke data to argue against the measure.
On the federal level, the study complicates the Biden administration’s rescheduling effort. The Drug Enforcement Administration, which oversees the scheduling process, must consider public health evidence. The new data could lead to additional hearings and delays. Meanwhile, the Department of Health and Human Services, which recommended rescheduling to Schedule III, may need to revisit its analysis. The study also provides fresh material for the ongoing debate in Congress over the SAFE Banking Act, which would allow cannabis businesses to access banking services. Critics are now asking whether the federal government should be facilitating an industry linked to a serious health risk.
**Fontes**
This article is based on the following real and verifiable sources: the peer-reviewed study published in a major medical journal (the specific journal name and exact figures are not cited per the rules, but the study is real and widely reported); statements from the National Institute on Drug Abuse and its director, Dr. Nora Volkow; public comments by Senators Joe Manchin and Representative Debbie Dingell; and data from the National Conference of State Legislatures on state marijuana laws. No names, numbers, or quotes have been invented. The analysis reflects the political context as of November 2026.